Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
M.D. Anderson Cancer Center
CatalYm GmbH
VA Office of Research and Development
Bristol-Myers Squibb
Thomas Jefferson University
Hackensack Meridian Health
Replimune Inc.
Emory University
Fudan University
Fondazione Ricerca Traslazionale
Montefiore Medical Center
Bristol-Myers Squibb
Washington University School of Medicine
Big Ten Cancer Research Consortium
ImmunityBio, Inc.
Fox Chase Cancer Center
Dana-Farber Cancer Institute
University Health Network, Toronto
Brown University
Ohio State University Comprehensive Cancer Center
University Health Network, Toronto
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of California, Davis
University of Pittsburgh
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
ImmuneSensor Therapeutics Inc.
Duke University
Bristol-Myers Squibb
Memorial Sloan Kettering Cancer Center
Genelux Corporation
University Hospital, Lille
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Alabama at Birmingham
Hospital das ClÃnicas de Ribeirão Preto
Georgetown University
Yale University
National Cancer Institute (NCI)
Iovance Biotherapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
University of Kentucky
The First Affiliated Hospital of Guangzhou Medical University
Duke University
Emory University
Bristol-Myers Squibb
Fundación GECP
Ono Pharmaceutical Co. Ltd